GCM
BCRX icon

Graham Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Graham Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83,876
Closed -$654K – 1180
2025
Q4 		$654K Sell
83,876
-183,854
-69% -$1.33M 0.02% 527
2025
Q3 		$2.03M Buy
267,730
+48,646
+22% +$405K 0.03% 231
2025
Q2 		$1.96M Buy
219,084
+82,981
+61% +$773K 0.03% 364
2025
Q1 		$1.02M Buy
136,103
+38,846
+40% +$313K 0.02% 542
2024
Q4 		$731K Buy
+97,257
New +$738K 0.01% 592
2024
Q1 		– Sell
-64,856
Closed -$388K – 1063
2023
Q4 		$388K Buy
64,856
+27,330
+73% +$158K 0.01% 662
2023
Q3 		$266K Sell
37,526
-111
-0.3% -$798 0.01% 761
2023
Q2 		$265K Buy
+37,637
New +$302K 0.01% 727
2022
Q4 		– Sell
-24,972
Closed -$314K – 1056
2022
Q3 		$314K Sell
24,972
-137,741
-85% -$1.77M 0.01% 890
2022
Q2 		$1.72M Buy
+162,713
New +$1.68M 0.07% 253

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Graham Capital Management's BCRX Position: Q1 2026 in Review

Graham Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 83,876 shares — an estimated $654K sold.

Graham Capital Management first reported a position in BCRX in Q2 2022 and held it in 10 quarters. The position peaked at $2.03M in Q3 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Graham Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 83,876 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $654K.
  • Graham Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 10 quarters.
  • Graham Capital Management's BioCryst Pharmaceuticals position peaked at $2.03M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.